Douglas E. Onsi has been the CEO of Leap Therapeutics, Inc. since April 2020. He holds a Bachelor’s degree in Finance from the University of Michigan and has a solid background in finance, having previously served as Chief Financial Officer...

Douglas E. Onsi has been the CEO of Leap Therapeutics, Inc. since April 2020. He holds a Bachelor’s degree in Finance from the University of Michigan and has a solid background in finance, having previously served as Chief Financial Officer of Leap. Before joining Leap, he was a managing director at HealthCare Ventures and held various roles at Genzyme Corporation, focusing on oncology product operations and business development. His leadership style emphasizes aligning the company’s goals with shareholders' interests, which is seen in the way he guides Leap towards clinical and financial milestones. Interestingly, throughout his time at Leap, he has engaged in significant insider trading activities, reflecting his confidence in the company’s future. In 2023, he received over $1.3 million in total compensation, composed primarily of salary and bonuses based on performance metrics set by the board, which included clinical study completions and new product developments. Douglas is also noteworthy for his strategic decisions regarding stock options and has a vested interest in the company’s stock, facilitating a deep connection between executive decisions and investor returns. This approach gives him a unique perspective on leading Leap Therapeutics as it navigates the complexities of the biopharmaceutical landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Leap Therapeutics, Inc. CEOs

L

Douglas E. Onsi

CEO of Leap Therapeutics, Inc.

Education

B.S. in Finance from University of Michigan

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1974 - 51 years ago

CEO of Leap Therapeutics, Inc. for

5 years 2 months (Apr 2020 - Present)

Previous Experience

Chief Financial Officer, Treasurer and Secretary of Leap Therapeutics, Inc.

Rivals

Competitors/colleagues of Douglas E. Onsi

P

Michael Amoroso

CEO of Precision BioSciences, Inc.

2023 Compensation

Stock

$0.00

Salary

$629.92K

Bonus

$381.00K

Other

$60.39K

Total Holdings

$1.07M

Holdings

See how much did Douglas E. Onsi make over time.

Douglas E. Onsi has shown a remarkable engagement in Leap Therapeutics' stock, with his holdings reaching peaks worth around $10 million in the early months of 2021. Since becoming CEO, he has negotiated favorable insider trading moves, reflecting confidence in...

Douglas E. Onsi has shown a remarkable engagement in Leap Therapeutics' stock, with his holdings reaching peaks worth around $10 million in the early months of 2021. Since becoming CEO, he has negotiated favorable insider trading moves, reflecting confidence in Leap's trajectory. Notably, from 2019 to now, there have been significant fluctuations in his trading activities, with the highest values registered above $10 million in 2021 alone. In recent years, this value has decreased, reflecting the ups and downs often faced in the biopharmaceutical sector. As of 2023, his trading activities have tapered, indicating potential shifts in strategy or immediate financial landscapes yet holding onto substantial residual equity value. Overall, his holdings display an ongoing investment in Leap's potential and a commitment to its long-term success.

Mar 18, 2025

L

shares

LPTX @ $0.41

Insider Trading

See recent insider trades of Douglas E. Onsi.

LPTX

$1.00M

LPTX at $1.75/share

Feb 5, 2019

Purchase

LPTX

$6.44M

LPTX at $6.09/share

Nov 14, 2017

Purchase

Compensation History

See how much did Douglas E. Onsi make over time.

In 2023, Douglas E. Onsi was compensated a total of $1.35 million, which included a base salary of $675,000. This salary reflects his increased responsibilities since taking over as CEO of Leap Therapeutics. He also earned a performance-based bonus of $368,041, which highlights his success in meeting corporate objectives set by the board. Notably, Onsi’s compensation package did not include any stock grants in 2023, focusing on cash incentives instead. Less about the investments, his compensation reflects the board’s strategy to motivate and reward executives based on company performance, which relates closely to shareholder interests. This pay-for-performance approach is a cornerstone of Leap’s executive compensation philosophy, aiming to align leadership success with company growth and stockholder returns. Overall, Onsi's compensation package paints a picture of a leader incentivized to drive long-term value for Leap and its shareholders.

Year

2023

Total Compensation

$1.10M

Salary

$675.00K

Board Justification

The executive compensation program is designed to attract and retain a highly skilled team of key executives and to align the compensation of our executives with the interests of our stockholders by rewarding the achievement of short- and long-term strategic financial goals.

Bonus

$368.04K

Board Justification

This column represents the cash incentive bonus payments for 2023 made to each executive, based on the achievement of corporate objectives established by the Board.

Other

$58.06K

Board Justification

Other compensation includes 401(k) matching, payment of medical and dental insurance, Company HSA contribution, life insurance, and Paid Medical Leave.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and not on stock grants or options.

Performance Metrics

The corporate objectives for 2023 included completion of enrollment in the 160 patient randomized controlled Part C of the DisTinGuish study, the completion of enrollment in the 33 patient Part A of the DeFianCe study, development of a new manufacturing process for our DKN-01 monoclonal antibody, and generating preclinical data for the early stage pipeline.

Other Leap Therapeutics, Inc. CEOs

Here are other CEOs of Leap Therapeutics, Inc.

Christopher K. Mirabelli, Ph.D.

Ex-CEO of Leap Therapeutics, Inc.

August 2016 - April 2020